Want to see NERV full AI Analyst Report?
NERV Stock Chart & Stats
$5.43
$0.20(4.95%)
At close: 4:00 PM EDT
$5.43
$0.20(4.95%)
Day’s Range― - ―
52-Week Range$1.93 - $12.46
Previous CloseN/A
Volume117.94K
Average Volume (3M)219.32K
Market Cap
$213.91M
Enterprise Value$435.40
Total Cash (Recent Filing)$75.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.37
Shares Outstanding47,747,560
10 Day Avg. Volume357,051
30 Day Avg. Volume219,319
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside56.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused CNS PipelineA defined CNS focus gives Minerva a clear therapeutic identity and allows limited R&D resources to target specific psychiatric and neurological needs. Successful development could create meaningful strategic value from its specialized pipeline.
Accounting LeadershipSeparating accounting leadership from the CFO role may strengthen internal controls, reporting discipline and oversight. This is particularly relevant for a capital-intensive clinical company that must maintain reliable financial disclosures.
Governance And Audit OversightContinuity with the independent auditor and updated charter and bylaw provisions can improve governance clarity and shareholder processes. These measures support compliance and oversight as the company advances its development programs.
Bears Say
No Recurring RevenueWithout product revenue, Minerva lacks an established operating funding source and remains dependent on clinical progress and external capital. This makes financial performance highly sensitive to development outcomes and financing availability.
Persistent Losses And Cash BurnSustained operating losses and negative cash flow show that the business is consuming capital rather than funding development internally. Continued burn can constrain pipeline investment and increase the need for dilutive or otherwise costly financing.
Negative EquityWorsening negative equity signals a strained capital structure and reduces financial flexibility. Although debt is mostly low or zero outside 2025, the weak equity position still increases reliance on external funding to sustain operations.
Minerva Neurosciences News
NERV FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $1.93 and its highest was $12.46 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Minerva Neurosciences’s market cap is $213.91M.
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is Nov 11, 2026 which is in 69 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on Aug 07, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.053.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate is -0.17.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 47,747,560 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went down -3.829%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in NERV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Minerva Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (56.54% Upside)
$8.50 (56.54% Upside)
Blogger Sentiment
Bullish
NERV Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
97.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
212.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
NERV Stock 12 Month Forecast
Average Price Target
$8.50
▲(56.54% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Pulmatrix
―
Chemomab Therapeutics
―
―
Aspire Biopharma Holdings
―
Ownership Overview
1.00%
Insiders
5.08% Mutual Funds
44.27% Other Institutional Investors
42.89% Public Companies and
Individual Investors